First Long Island Investors LLC Invests $4.83 Million in Allergan PLC. (NYSE:AGN)
First Long Island Investors LLC acquired a new position in shares of Allergan PLC. (NYSE:AGN) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 20,200 shares of the company’s stock, valued at approximately $4,826,000.
A number of other large investors have also recently made changes to their positions in AGN. Crestwood Advisors Group LLC purchased a new stake in shares of Allergan PLC. during the first quarter worth about $103,000. Feltz Wealth PLAN Inc. purchased a new stake in shares of Allergan PLC. during the first quarter worth about $107,000. Enterprise Financial Services Corp boosted its stake in shares of Allergan PLC. by 62.7% in the first quarter. Enterprise Financial Services Corp now owns 462 shares of the company’s stock worth $110,000 after buying an additional 178 shares in the last quarter. JNBA Financial Advisors boosted its stake in shares of Allergan PLC. by 2.5% in the first quarter. JNBA Financial Advisors now owns 487 shares of the company’s stock worth $116,000 after buying an additional 12 shares in the last quarter. Finally, Webster Bank N. A. boosted its stake in shares of Allergan PLC. by 31.0% in the first quarter. Webster Bank N. A. now owns 520 shares of the company’s stock worth $124,000 after buying an additional 123 shares in the last quarter. Institutional investors and hedge funds own 84.53% of the company’s stock.
Allergan PLC. (AGN) opened at 245.85 on Friday. Allergan PLC. has a one year low of $184.50 and a one year high of $261.27. The stock’s 50 day moving average price is $231.35 and its 200 day moving average price is $230.10. The stock has a market cap of $82.57 billion, a price-to-earnings ratio of 7.66 and a beta of 1.16.
Allergan PLC. (NYSE:AGN) last issued its earnings results on Tuesday, May 9th. The company reported $3.35 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.32 by $0.03. The company had revenue of $3.57 billion for the quarter, compared to the consensus estimate of $3.53 billion. Allergan PLC. had a return on equity of 7.29% and a net margin of 82.42%. The firm’s quarterly revenue was up 5.1% on a year-over-year basis. During the same quarter last year, the company earned $3.04 EPS. Equities analysts predict that Allergan PLC. will post $16.09 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: This article was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another publication, it was illegally copied and reposted in violation of international copyright and trademark legislation. The original version of this article can be read at https://www.thecerbatgem.com/2017/07/16/first-long-island-investors-llc-invests-4-83-million-in-allergan-plc-nyseagn.html.
A number of equities research analysts recently issued reports on the company. UBS AG restated a “buy” rating and issued a $275.00 price objective on shares of Allergan PLC. in a research note on Monday, May 15th. Vetr upgraded Allergan PLC. from a “sell” rating to a “hold” rating and set a $242.88 price objective on the stock in a research note on Monday, June 26th. Deutsche Bank AG boosted their price objective on Allergan PLC. from $262.00 to $265.00 and gave the company a “buy” rating in a research note on Tuesday, March 28th. Royal Bank Of Canada set a $284.00 price objective on Allergan PLC. and gave the company a “buy” rating in a research note on Monday, June 12th. Finally, BidaskClub upgraded Allergan PLC. from a “hold” rating to a “buy” rating in a research note on Saturday, June 24th. Seven research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $272.73.
In related news, Director Nesli Basgoz sold 1,889 shares of Allergan PLC. stock in a transaction that occurred on Thursday, May 18th. The stock was sold at an average price of $220.45, for a total transaction of $416,430.05. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 0.36% of the stock is currently owned by company insiders.
About Allergan PLC.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Stock Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related stocks with our FREE daily email newsletter.